BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. Mov Disord 2021;36:25-36. [PMID: 33314312 DOI: 10.1002/mds.28411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Blesa J, Foffani G, Dehay B, Bezard E, Obeso JA. Motor and non-motor circuit disturbances in early Parkinson disease: which happens first? Nat Rev Neurosci 2021. [PMID: 34907352 DOI: 10.1038/s41583-021-00542-9] [Reference Citation Analysis]
2 Liu Z, Fan Q, Wu S, Wan Y, Lei Y. Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson's disease. Lipids Health Dis 2021;20:35. [PMID: 33874966 DOI: 10.1186/s12944-021-01462-4] [Reference Citation Analysis]
3 Shannon KM. Gut-Derived Sterile Inflammation and Parkinson's Disease. Front Neurol 2022;13:831090. [DOI: 10.3389/fneur.2022.831090] [Reference Citation Analysis]
4 Saxena A, Paredes-Echeverri S, Michaelis R, Popkirov S, Perez DL. Using the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments. Semin Neurol 2022. [PMID: 35114695 DOI: 10.1055/s-0041-1742145] [Reference Citation Analysis]
5 Kasen A, Houck C, Burmeister AR, Sha Q, Brundin L, Brundin P. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105654] [Reference Citation Analysis]
6 Li Y, Li Z, Gu J, Xu X, Chen H, Gui Y. Exosomes isolated during dopaminergic neuron differentiation suppressed neuronal inflammation in a rodent model of Parkinson's disease. Neurosci Lett 2021;771:136414. [PMID: 34954117 DOI: 10.1016/j.neulet.2021.136414] [Reference Citation Analysis]
7 Marchetti B, Giachino C, Tirolo C, Serapide MF. "Reframing" dopamine signaling at the intersection of glial networks in the aged Parkinsonian brain as innate Nrf2/Wnt driver: Therapeutical implications. Aging Cell 2022;:e13575. [PMID: 35262262 DOI: 10.1111/acel.13575] [Reference Citation Analysis]
8 Caldi Gomes L, Galhoz A, Jain G, Roser AE, Maass F, Carboni E, Barski E, Lenz C, Lohmann K, Klein C, Bähr M, Fischer A, Menden MP, Lingor P. Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease. Clin Transl Med 2022;12:e692. [PMID: 35090094 DOI: 10.1002/ctm2.692] [Reference Citation Analysis]
9 Mourad M, Passley TM, Purcell JM, Leheste JR. Early-Onset Parkinson's Disease With Multiple Positive Intraoperative Spinal Tissue Cultures for Cutibacterium acnes. Cureus 2021;13:e17607. [PMID: 34646658 DOI: 10.7759/cureus.17607] [Reference Citation Analysis]
10 Zhao Y, Zhang X, Guo N, Tian D, Zhang C, Mu C, Han C, Zhu R, Zhang J, Liu X. Genetically Predicted Levels of Circulating Inflammatory Cytokines and the Risk and Age at Onset of Parkinson’s Disease: A Two-Sample Mendelian Randomization Study. Front Aging Neurosci 2022;14:811059. [DOI: 10.3389/fnagi.2022.811059] [Reference Citation Analysis]
11 Wallin J, Svenningsson P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease. Int J Mol Sci 2021;22:5606. [PMID: 34070609 DOI: 10.3390/ijms22115606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing Parkinson's Disease: An Environmental Agenda. J Parkinsons Dis 2021. [PMID: 34719434 DOI: 10.3233/JPD-212922] [Reference Citation Analysis]
13 Iarkov A, Mendoza C, Echeverria V. Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease. Front Neurosci 2021;15:665820. [PMID: 34616271 DOI: 10.3389/fnins.2021.665820] [Reference Citation Analysis]
14 Li L, Wang H, Li H, Lu X, Gao Y, Guo X. Long noncoding RNA BACE1-antisense transcript plays a critical role in Parkinson's disease via microRNA-214-3p/Cell death-inducing p53-target protein 1 axis. Bioengineered 2022;13:10889-901. [PMID: 35481549 DOI: 10.1080/21655979.2022.2066750] [Reference Citation Analysis]
15 Sarkar S, Feany MB. Precision Medicine on the Fly: Using Drosophila to Decipher Gene-Environment Interactions in Parkinson's Disease. Toxicol Sci 2021;182:159-67. [PMID: 34076689 DOI: 10.1093/toxsci/kfab060] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Miao Z, Bai J, Shen L, Singla RK. The Combination of Tradition and Future: Data-Driven Natural-Product-Based Treatments for Parkinson's Disease. Evid Based Complement Alternat Med 2021;2021:9990020. [PMID: 34335855 DOI: 10.1155/2021/9990020] [Reference Citation Analysis]
17 Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 2022. [PMID: 35246670 DOI: 10.1038/s41577-022-00684-6] [Reference Citation Analysis]
18 Sandoval IM, Marmion DJ, Meyers KT, Manfredsson FP. Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies. J Parkinsons Dis 2021. [PMID: 34092656 DOI: 10.3233/JPD-212679] [Reference Citation Analysis]